Literature DB >> 31767492

Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation.

Bas Israël1, Marloes van der Leest1, Michiel Sedelaar2, Anwar R Padhani3, Patrik Zámecnik1, Jelle O Barentsz4.   

Abstract

BACKGROUND: There is large variability among radiologists in their detection of clinically significant (cs) prostate cancer (PCa) on multiparametric magnetic resonance imaging (mpMRI).
OBJECTIVE: To reduce the interpretation variability and achieve optimal accuracy in assessing prostate mpMRI. DESIGN, SETTING, AND PARTICIPANTS: How the interpretation of mpMRI can be optimized is demonstrated here. Whereas part 1 of the "surgery-in-motion" paper focused on acquisition, this paper shows the correlation between (ab)normal prostate anatomical structures and image characteristics on mpMRI, and how standardized interpretation according to Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) should be performed. This will be shown in individual patients. SURGICAL PROCEDURE: To detect csPCa, three mpMRI "components" are used: "anatomic" T2-weighted imaging, "cellular-density" diffusion-weighted imaging, and "vascularity" dynamic contrast-enhanced MRI. MEASUREMENTS: Based on PI-RADS v2, the accompanying video shows how mpMRI interpretation is performed. Finally, the role of mpMRI in detecting csPCa is briefly discussed and the main features of the recently introduced PI-RADS v2.1 are evaluated. RESULTS AND LIMITATIONS: With PI-RADS v2, it is possible to quantify normal and abnormal anatomical structures within the prostate based on its imaging features of the three mpMRI "components." With this knowledge, a more objective evaluation of the presence of a csPCa can be performed. However, there still remains quite some space to reduce interobserver variability.
CONCLUSIONS: For understanding the interpretation of mpMRI according to PI-RADS v2, knowledge of the correlation between imaging and (ab)normal anatomical structures on the three mpMRI components is needed. PATIENT
SUMMARY: This second surgery-in-motion contribution shows what structures can be recognized on prostate magnetic resonance imaging (MRI). How a radiologist performs his reading according to the so-called Prostate Imaging Reporting and Data System criteria is shown here. The main features of these criteria are summarized, and the role of prostate MRI in detecting clinically significant prostate cancer is discussed briefly.
Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Interpretation prostate imaging reporting and data system version 2; Magnetic resonance imaging; Multiparametric magnetic resonance imaging; Prostate cancer; Prostate imaging reporting and data system

Mesh:

Year:  2019        PMID: 31767492     DOI: 10.1016/j.eururo.2019.10.024

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

Review 1.  The role of radiomics in prostate cancer radiotherapy.

Authors:  Rodrigo Delgadillo; John C Ford; Matthew C Abramowitz; Alan Dal Pra; Alan Pollack; Radka Stoyanova
Journal:  Strahlenther Onkol       Date:  2020-08-21       Impact factor: 3.621

2.  MRI as a screening tool for prostate cancer: current evidence and future challenges.

Authors:  Christoph Würnschimmel; Thenappan Chandrasekar; Luisa Hahn; Tarik Esen; Shahrokh F Shariat; Derya Tilki
Journal:  World J Urol       Date:  2022-02-28       Impact factor: 4.226

Review 3.  More than Meets the Eye: Using Textural Analysis and Artificial Intelligence as Decision Support Tools in Prostate Cancer Diagnosis-A Systematic Review.

Authors:  Teodora Telecan; Iulia Andras; Nicolae Crisan; Lorin Giurgiu; Emanuel Darius Căta; Cosmin Caraiani; Andrei Lebovici; Bianca Boca; Zoltan Balint; Laura Diosan; Monica Lupsor-Platon
Journal:  J Pers Med       Date:  2022-06-16

4.  The value of magnetic resonance imaging-ultrasound fusion targeted biopsies for clinical decision-making among patients with previously negative transrectal ultrasound biopsy and persistent prostate-specific antigen elevation.

Authors:  Charlie J Gillis; Thomas M Southall; Robert Wilson; Michelle Anderson; Jennifer Young; Richard Hewitt; Matthew Andrews
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

5.  Prostate cancer: diagnostic yield of modified transrectal ultrasound-guided twelve-core combined biopsy (targeted plus systematic biopsies) using prebiopsy magnetic resonance imaging.

Authors:  Chorog Song; Sung Yoon Park
Journal:  Abdom Radiol (NY)       Date:  2021-06-28

6.  Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.

Authors:  M Boschheidgen; L Schimmöller; S Doerfler; R Al-Monajjed; J Morawitz; F Ziayee; D Mally; M Quentin; C Arsov; P Albers; G Antoch; T Ullrich
Journal:  Sci Rep       Date:  2022-04-25       Impact factor: 4.996

7.  Computer-aided diagnosis of prostate cancer based on deep neural networks from multi-parametric magnetic resonance imaging.

Authors:  Zhenglin Yi; Zhenyu Ou; Jiao Hu; Dongxu Qiu; Chao Quan; Belaydi Othmane; Yongjie Wang; Longxiang Wu
Journal:  Front Physiol       Date:  2022-08-29       Impact factor: 4.755

8.  Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer.

Authors:  Bas Israël; Jos Immerzeel; Marloes van der Leest; Gerjon Hannink; Patrik Zámecnik; Joyce Bomers; Ivo G Schoots; Jean-Paul van Basten; Frans Debruyne; Inge van Oort; Michiel Sedelaar; Jelle Barentsz
Journal:  BJU Int       Date:  2021-08-23       Impact factor: 5.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.